CA2300362A1 - Coat-protein-modified baculovirus vector for gene therapy - Google Patents
Coat-protein-modified baculovirus vector for gene therapy Download PDFInfo
- Publication number
- CA2300362A1 CA2300362A1 CA002300362A CA2300362A CA2300362A1 CA 2300362 A1 CA2300362 A1 CA 2300362A1 CA 002300362 A CA002300362 A CA 002300362A CA 2300362 A CA2300362 A CA 2300362A CA 2300362 A1 CA2300362 A1 CA 2300362A1
- Authority
- CA
- Canada
- Prior art keywords
- vector
- sequence
- vector according
- dna sequence
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1997135593 DE19735593C2 (de) | 1997-08-15 | 1997-08-15 | Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie |
DE19735593.5 | 1997-08-15 | ||
PCT/DE1998/002255 WO1999009193A1 (de) | 1997-08-15 | 1998-08-05 | Hüllprotein-modifizierter baculovirus-vektor für die gentherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2300362A1 true CA2300362A1 (en) | 1999-02-25 |
Family
ID=7839201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002300362A Abandoned CA2300362A1 (en) | 1997-08-15 | 1998-08-05 | Coat-protein-modified baculovirus vector for gene therapy |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1003896A1 (de) |
JP (1) | JP2003530064A (de) |
CA (1) | CA2300362A1 (de) |
DE (1) | DE19735593C2 (de) |
ES (1) | ES2150894T1 (de) |
WO (1) | WO1999009193A1 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6183993B1 (en) * | 1996-09-11 | 2001-02-06 | The General Hospital Corporation | Complement-resistant non-mammalian DNA viruses and uses thereof |
GB0012997D0 (en) * | 2000-05-26 | 2000-07-19 | Eurogene Limited | Gene delivery |
US6607912B2 (en) | 2000-08-11 | 2003-08-19 | Boyce Thompson Institute For Plant Research, Inc. | GP64-null baculoviruses pseudotyped with heterologous envelope proteins |
WO2002072853A1 (en) * | 2001-03-12 | 2002-09-19 | Ark Therapeutics Limited | Avidin-pseudotyped viral vectors and their use |
WO2002096469A2 (en) * | 2001-05-29 | 2002-12-05 | Ark Therapeutics Ltd. | Gene delivery via a baculovirus vector |
GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
US6863884B2 (en) | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
EP1548119A4 (de) * | 2002-09-25 | 2006-08-02 | Osaka Ind Promotion Org | Baculovirusvektor, verfahren zur konstruktion des baculovirusvektors und gentransfer-verfahren |
US7416890B2 (en) | 2002-09-25 | 2008-08-26 | Osaka Industrial Promotion Organization | Baculovirus vector, method of producing thereof and method of gene transfer |
AU2005319099B2 (en) | 2004-02-02 | 2010-09-16 | Ambrx, Inc. | Modified human growth hormone |
AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
CA2568952C (en) | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
GB0425739D0 (en) * | 2004-11-23 | 2004-12-22 | Procure Therapeutics Ltd | Humanised baculovirus 2 |
JP5425398B2 (ja) | 2004-12-22 | 2014-02-26 | アンブレツクス・インコーポレイテツド | 非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用 |
EP1836316A4 (de) | 2004-12-22 | 2009-07-22 | Ambrx Inc | Verfahren zur expression und reinigung von rekombinantem menschlichem wachstumshormon |
NZ555386A (en) | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
JP4990792B2 (ja) | 2004-12-22 | 2012-08-01 | アンブレツクス・インコーポレイテツド | アミノアシル−tRNAシンテターゼの組成物およびこの使用 |
ATE529442T1 (de) | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
EP1951890A4 (de) | 2005-11-16 | 2009-06-24 | Ambrx Inc | Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren |
TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
EP2615108B1 (de) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen |
DK2061878T3 (da) | 2006-09-08 | 2014-04-07 | Ambrx Inc | Hybridsuppressor-trna for hvirveldyrceller |
ATE554785T1 (de) | 2007-03-30 | 2012-05-15 | Ambrx Inc | Modifizierte fgf-21 polypeptide und ihre verwendung |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
EP2930182A1 (de) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modifizierte insulinpolypeptide und deren verwendungen |
SG188143A1 (en) | 2008-02-08 | 2013-03-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
CN102232085A (zh) | 2008-09-26 | 2011-11-02 | Ambrx公司 | 修饰的动物促红细胞生成素多肽和其用途 |
MX2011003196A (es) | 2008-09-26 | 2011-04-27 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
MX349301B (es) | 2009-12-21 | 2017-07-21 | Ambrx Inc | Polipéptidos de somatotropina bovina modificados y sus usos. |
BR112012015597A2 (pt) | 2009-12-21 | 2017-01-31 | Ambrx Inc | peptídeos de somatotropina suínos modificados e seus usos |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
JPWO2016059911A1 (ja) * | 2014-10-17 | 2017-07-27 | 国立大学法人金沢大学 | マラリアワクチン |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4407859C1 (de) * | 1994-03-04 | 1995-03-02 | Max Planck Gesellschaft | Vektor für die leberspezifische Gentherapie |
AU702830B2 (en) * | 1994-09-23 | 1999-03-04 | General Hospital Corporation, The | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
US5750383A (en) * | 1996-05-14 | 1998-05-12 | Boyce Thompson Institute For Plant Research, Inc. | Baculovirus cloning system |
-
1997
- 1997-08-15 DE DE1997135593 patent/DE19735593C2/de not_active Expired - Fee Related
-
1998
- 1998-08-05 CA CA002300362A patent/CA2300362A1/en not_active Abandoned
- 1998-08-05 ES ES98947386T patent/ES2150894T1/es active Pending
- 1998-08-05 EP EP98947386A patent/EP1003896A1/de not_active Withdrawn
- 1998-08-05 JP JP2000509856A patent/JP2003530064A/ja active Pending
- 1998-08-05 WO PCT/DE1998/002255 patent/WO1999009193A1/de not_active Application Discontinuation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2150894T1 (es) | 2000-12-16 |
EP1003896A1 (de) | 2000-05-31 |
WO1999009193A1 (de) | 1999-02-25 |
DE19735593A1 (de) | 1999-02-18 |
DE19735593C2 (de) | 1999-08-26 |
JP2003530064A (ja) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2300362A1 (en) | Coat-protein-modified baculovirus vector for gene therapy | |
CA2148934C (en) | Targetable vector particles | |
JP3681752B2 (ja) | 遺伝子治療に使用できる宿主 − ベクタ系 | |
US20050181507A1 (en) | Gene delivery vectors with cell type specificity for mesenchymal stem cells | |
EP0851769B1 (de) | Gentherapie mit hilfe von schaf-adenoviralen vektoren | |
WO2001058940A2 (en) | Adenoviral capsid containing chimeric protein ix | |
IL214413A (en) | Human Recombinant Human Adenovirus Type 35, Nucleic Acid Encoded, Nucleic Acid Cell and Method | |
JP2001522236A (ja) | 改変アデノウイルスファイバーおよび標的アデノウイルス | |
US6872528B2 (en) | Highly productive packaging lines | |
AU2002315947A1 (en) | Adenoviral vectors with cell type specificity for mesenchymal cells | |
AU717202B2 (en) | New variants of apolipoprotein A-I | |
US7410954B2 (en) | Adenovirus serotype 30 (Ad30) | |
US5736360A (en) | Endothelial cell tropic compositions and methods of making and using the same | |
AU729934B2 (en) | Retroviral vector and its use in gene therapy | |
WO1998047916A1 (en) | Bifunctional polypeptides for cell-specific viral targeting | |
JP2000157289A (ja) | 平滑筋細胞および/または内皮細胞への組織向性を与えられた遺伝子送達ベクタ― | |
AU747763B2 (en) | Method for helper virus-free packaging of a gene vector DNA | |
CA2131415C (en) | Vector for liver-specific gene therapy | |
US20020137213A1 (en) | Adenovirus particles with mutagenized fiber proteins | |
EP1279738A1 (de) | Für mesenchymale Stammzellen spezifische Gen-Transfer-Vektoren | |
EP1195440A1 (de) | Genverabreichung-Vektoren für Stammzellen | |
CA2047363C (en) | Recombinant therapies for infection and hyperproliferative disorders | |
EP0870050A2 (de) | Toxisches protein exprimierende viren und produktionszellinien | |
Michael | Development of tropism-modified adenoviral vectors for targeted gene delivery | |
Lea et al. | The Scope of Viral Vectors for the Transduction of Haemopoietic Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |